Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice

Regulatory Peptides

Volumn 190-191, Issue , 2014, Pages 25-31

  Darsalia, Vladimer ^a   Olverling, Anna ^a   Larsson, Martin ^a   Mansouri, Shiva ^a   Nathanson, David ^a   Nyström, Thomas ^a   Klein, Thomas ^b   Sjöholm, Åke ^c,d   Patrone, Cesare ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

^d Division of Obstetrics and Gynecology Södertälje Hospital   (Sweden)

Author keywords

DPP 4 inhibitor; GLP 1; High fat diet; Linagliptin; MCAO; Stroke

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; LINAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CELL PROLIFERATION; CELL VIABILITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG INHIBITION; IN VITRO STUDY; INSULIN RELEASE; LIPID DIET; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROBLAST; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL SURVIVAL; COMPLICATION; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; NEURAL STEM CELLS; PURINES; QUINAZOLINES; STROKE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84901004797     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2014.05.001     Document Type: Article

References (62)

1. Sander D., Kearney M.T. Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. J Neurol 2009, 256:1603-1619.
2. Marini C., Baldassarre M., Russo T., De Santis F., Sacco S., Ciancarelli I., Carolei A. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology 2004, 62:77-81.
3. Luitse M.J., Biessels G.J., Rutten G.E., Kappelle L.J. Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol 2012, 11:261-271.
4. Deacon C.F. What do we know about the secretion and degradation of incretin hormones?. Regul Pept 2005, 128:117-124.
5. Hansen L., Deacon C.F., Orskov C., Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
6. Rocca A.S., Brubaker P.L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999, 140:1687-1694.
7. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
8. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993, 214:829-835.
9. Ahren B., Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004, 36:867-876.
10. Siddiqui N.I. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh Med J 2009, 18:113-124.
11. Verspohl E.J. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009, 124:113-138.
12. Duez H., Cariou B., Staels B. DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem Pharmacol 2012, 83:823-832.
13. Sarashina A., Sesoko S., Nakashima M., Hayashi N., Taniguchi A., Horie Y., Graefe-Mody E.U., Woerle H.J., Dugi K.A. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther 2010, 32:1188-1204.
14. Deacon C.F., Holst J.J. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010, 19:133-140.
15. McGill J.B. Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials. Ther Adv Endocrinol Metab 2012, 3:113-124.
16. Holscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol 2014, 221:T31-T41.
17. Harkavyi A., Whitton P.S. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 2010, 159:495-501.
18. Salcedo I., Tweedie D., Li Y.Z., Greig N.H. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 2012, 166:1586-1599.
19. Holst J.J., Burcelin R., Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011, 27:547-558.
20. Patrone C., Eriksson O., Lindholm D. Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol 2014, 2:256-262.
21. Hunter K., Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012, 13:33.
22. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003, 27:313-318.
23. Darsalia V., Ortsater H., Olverling A., Darlof E., Wolbert P., Nystrom T., Klein T., Sjoholm A., Patrone C. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes 2013, 62:1289-1296.
24. Darsalia V., Mansouri S., Ortsater H., Olverling A., Nozadze N., Kappe C., Iverfeldt K., Tracy L.M., Grankvist N., Sjoholm A., Patrone C. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond) 2012, 122:473-483.
25. Lee C.H., Yan B., Yoo K.Y., Choi J.H., Kwon S.H., Her S., Sohn Y., Hwang I.K., Cho J.H., Kim Y.M., Won M.H. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res 2011, 89:1103-1113.
26. Teramoto S., Miyamoto N., Yatomi K., Tanaka Y., Oishi H., Arai H., Hattori N., Urabe T. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 2011, 31:1696-1705.
27. Sivertsen J., Rosenmeier J., Holst J.J., Vilsboll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012, 9:209-222.
28. Hou J., Manaenko A., Hakon J., Hansen-Schwartz J., Tang J., Zhang J.H. Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 2012, 32:2201-2210.
29. Parthsarathy V., Holscher C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol 2013, 700:42-50.
30. Ming G.L., Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 2011, 70:687-702.
31. Arvidsson A., Collin T., Kirik D., Kokaia Z., Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002, 8:963-970.
32. Parent J.M. Injury-induced neurogenesis in the adult mammalian brain. Neuroscientist 2003, 9:261-272.
33. Lindvall O., Kokaia Z. Stem cell research in stroke: how far from the clinic?. Stroke 2011, 42:2369-2375.
34. Bertilsson G., Patrone C., Zachrisson O., Andersson A., Dannaeus K., Heidrich J., Kortesmaa J., Mercer A., Nielsen E., Ronnholm H., Wikstrom L. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008, 86:326-338.
35. Hamilton A., Patterson S., Porter D., Gault V.A., Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res 2011, 89:481-489.
36. Isacson R., Nielsen E., Dannaeus K., Bertilsson G., Patrone C., Zachrisson O., Wikstrom L. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol 2011, 650:249-255.
37. Li H., Lee C.H., Yoo K.Y., Choi J.H., Park O.K., Yan B.C., Byun K., Lee B., Hwang I.K., Won M.H. Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus. Neurosci Lett 2010, 486:38-42.
38. Porter W.D., Flatt P.R., Holscher C., Gault V.A. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice. Int J Obes (Lond) 2013, 37:678-684.
39. Parthsarathy V., Holscher C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS One 2013, 8:e58784.
40. Rohnert P., Schmidt W., Emmerlich P., Goihl A., Wrenger S., Bank U., Nordhoff K., Tager M., Ansorge S., Reinhold D., Striggow F. Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J Neuroinflammation 2012, 9:44.
41. Yang D., Nakajo Y., Iihara K., Kataoka H., Yanamoto H. Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res 2013, 1517:104-113.
42. D'Amico M., Di Filippo C., Marfella R., Abbatecola A.M., Ferraraccio F., Rossi F., Paolisso G. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol 2010, 45:202-207.
43. Gallwitz B. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes Metab Syndr Obes Targets Ther 2013, 6:1-9.
44. Cabou C., Burcelin R. GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud 2011, 8:418-431.
45. Shannon R.P. DPP-4 inhibition and neuroprotection: do mechanisms matter?. Diabetes 2013, 62:1029-1031.
46. Lambeir A.M., Durinx C., Scharpe S., De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003, 40:209-294.
47. Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007, 30:1335-1343.
48. Hara H., Huang P.L., Panahian N., Fishman M.C., Moskowitz M.A. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab 1996, 16:605-611.
49. Mansouri S., Ortsater H., Pintor Gallego O., Darsalia V., Sjoholm A., Patrone C. Pituitary adenylate cyclase-activating polypeptide counteracts the impaired adult neural stem cell viability induced by palmitate. J Neurosci Res 2012, 90:759-768.
50. Mansouri S., Barde S., Ortsater H., Eweida M., Darsalia V., Langel U., Sjoholm A., Hokfelt T., Patrone C. GalR3 activation promotes adult neural stem cell survival in response to a diabetic milieu. J Neurochem 2013, 127:209-220.
51. Mansouri S., Ortsater H., Pintor Gallego O., Darsalia V., Sjoholm A., Patrone C. Pituitary adenylate cyclase-activating polypeptide counteracts the impaired adult neural stem cell viability induced by palmitate. J Neurosci Res 2012, 90(4):759-768.
52. Mercer A., Ronnholm H., Holmberg J., Lundh H., Heidrich J., Zachrisson O., Ossoinak A., Frisen J., Patrone C. PACAP promotes neural stem cell proliferation in adult mouse brain. J Neurosci Res 2004, 76:205-215.
53. Lagace D.C. Does the endogenous neurogenic response alter behavioral recovery following stroke?. Behav Brain Res 2012, 227:426-432.
54. Rivera P., Romero-Zerbo Y., Pavon F.J., Serrano A., Lopez-Avalos M.D., Cifuentes M., Grondona J.M., Bermudez-Silva F.J., Fernandez-Llebrez P., de Fonseca F.R., Suarez J., Perez-Martin M. Obesity-dependent cannabinoid modulation of proliferation in adult neurogenic regions. Eur J Neurosci 2011, 33:1577-1586.
55. Zhang R.L., Zhang Z.G., Zhang L., Chopp M. Proliferation and differentiation of progenitor cells in the cortex and the subventricular zone in the adult rat after focal cerebral ischemia. Neuroscience 2001, 105:33-41.
56. Jin K., Minami M., Lan J.Q., Mao X.O., Batteur S., Simon R.P., Greenberg D.A. Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proc Natl Acad Sci U S A 2001, 98:4710-4715.
57. Thored P., Arvidsson A., Cacci E., Ahlenius H., Kallur T., Darsalia V., Ekdahl C.T., Kokaia Z., Lindvall O. Persistent production of neurons from adult brain stem cells during recovery after stroke. Stem Cells 2006, 24:739-747.
58. Zhang R., Zhang Z., Zhang C., Zhang L., Robin A., Wang Y., Lu M., Chopp M. Stroke transiently increases subventricular zone cell division from asymmetric to symmetric and increases neuronal differentiation in the adult rat. J Neurosci 2004, 24:5810-5815.
59. Greischel A., Binder R., Baierl J. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats. Drug Metab Dispos 2010, 38:1443-1448.
60. Faivre E., Hamilton A., Holscher C. Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. Eur J Pharmacol 2012, 674:294-306.
61. Nyberg J., Anderson M.F., Meister B., Alborn A.M., Strom A.K., Brederlau A., Illerskog A.C., Nilsson O., Kieffer T.J., Hietala M.A., Ricksten A., Eriksson P.S. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci 2005, 25:1816-1825.
62. Burcelin R. The gut-brain axis: a major glucoregulatory player. Diabetes Metab 2010, 36(Suppl. 3):S54-S58.